Connor Clark & Lunn Investment Management Ltd. Decreases Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Connor Clark & Lunn Investment Management Ltd. reduced its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 72.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 163,886 shares of the biotechnology company's stock after selling 424,988 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.07% of ADMA Biologics worth $2,811,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Avantax Advisory Services Inc. lifted its stake in shares of ADMA Biologics by 8.3% during the 4th quarter. Avantax Advisory Services Inc. now owns 106,373 shares of the biotechnology company's stock worth $1,824,000 after acquiring an additional 8,109 shares during the last quarter. HighTower Advisors LLC raised its position in ADMA Biologics by 13.6% during the 4th quarter. HighTower Advisors LLC now owns 99,381 shares of the biotechnology company's stock valued at $1,704,000 after purchasing an additional 11,910 shares in the last quarter. Inspire Advisors LLC raised its position in ADMA Biologics by 7.3% during the 4th quarter. Inspire Advisors LLC now owns 22,394 shares of the biotechnology company's stock valued at $384,000 after purchasing an additional 1,532 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in ADMA Biologics by 7.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 65,960 shares of the biotechnology company's stock valued at $1,131,000 after purchasing an additional 4,586 shares in the last quarter. Finally, AlphaQuest LLC bought a new stake in ADMA Biologics during the 4th quarter valued at $84,000. 75.68% of the stock is owned by institutional investors.

Remove Ads

ADMA Biologics Stock Up 0.8 %

Shares of ADMA traded up $0.15 during trading hours on Friday, hitting $19.80. The company had a trading volume of 8,481,692 shares, compared to its average volume of 3,366,374. ADMA Biologics, Inc. has a one year low of $5.90 and a one year high of $23.64. The company's fifty day moving average price is $16.74 and its two-hundred day moving average price is $18.01. The company has a market capitalization of $4.68 billion, a PE ratio of 70.71 and a beta of 0.60. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $25.00 target price on shares of ADMA Biologics in a research report on Tuesday, March 4th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.